MondegarAI
BML Capital Management, LLC

Q4 2025 · 13F-HR

BML Capital Management, LLCholdings as filed

Filed 2026-02-03 · accession 0001754960-26-000146

$115.7M
Reported value
16
Positions
2025-12-31
Period end
View analyzed profile →PRO

The Brief · BML Capital Management, LLC · Q4 2025

AI · grounded in 13F

BML Capital Management, LLC closed its position in Adverum Biotechnologies Inc AVU0, reducing exposure by $13.85M. The fund established a new position in Carmax Inc KMX worth $5.99M and exited its holding in Alumis Inc ALMS for $4.83M. Other new entries include Carvana Co CVNA at $2.02M and Outset Med Inc OM at $2.02M.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
00461U105ACRSACLARIS THERAPEUTICS INC$42.9M37.1%14,250,000CommonNONE
04683R106AVIRATEA PHARMACEUTICALS INC$26.7M23.1%7,490,000CommonNONE
68403P203ORMPORAMED PHARMACEUTICALS INC$9.0M7.80%3,167,231CommonNONE
45783C200TILINSTIL BIO INC$7.1M6.14%645,600CommonNONE
69353Y103PMVPPMV PHARMACEUTICALS INC$6.6M5.72%5,292,000CommonNONE
143130102KMXCARMAX INC$6.0M5.18%155,000CommonNONE
49372L2092KZ0KEZAR LIFE SCIENCES INC$4.5M3.92%720,787CommonNONE
87612E106TGTTARGET CORP$3.7M3.17%37,500CommonNONE
146869102CVNACARVANA CO$2.0M1.74%150PUTNONE
690145206OMOUTSET MED INC$2.0M1.74%543,180CommonNONE
729139105PLRXPLIANT THERAPEUTICS INC$1.9M1.63%1,546,137CommonNONE
45175G207IMAIMAGENEBIO INC$1.2M1.06%177,026CommonNONE
G23549101CNTBCONNECT BIOPHARMA HLDGS LTD$1.2M1.00%408,887CommonNONE
931142103WMTWALMART INC$492,4500.43%335PUTNONE
88160R101TSLATESLA INC$205,0000.18%1,000PUTNONE
128058302LSTALISATA THERAPEUTICS INC$136,4270.12%73,348CommonNONE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.